CStone Pharmaceuticals (HK:2616) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CStone Pharmaceuticals has announced that its partner Jiangsu Hengrui Pharmaceuticals Co., Ltd. has begun a Phase III clinical trial for an anti-CTLA-4-based combination therapy as a first-line treatment for advanced hepatocellular carcinoma. The trial will assess the efficacy and safety of their investigational antibody, CS1002, in combination with other drugs, compared to existing treatments. CStone’s strategic partnership with Hengrui could lead to milestone payments up to approximately $200 million plus royalties, with CStone retaining rights outside Greater China.
For further insights into HK:2616 stock, check out TipRanks’ Stock Analysis page.